New treatment for fentanyl-related opioid use disorder using monoclonal antibodies
Antibody-based therapy for fentanyl-related opioid use disorder
This study is testing a new treatment called CSX-1004 that helps protect people from the dangerous effects of fentanyl, aiming to offer a longer-lasting solution for those at risk of overdose.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mclean Hospital NIH-funded |
| Lab location | 1 site (Belmont, United States) |
| Project ID | NIH-10831206 on NIH RePORTER |
What this research studies
This research investigates a novel monoclonal antibody therapy designed to combat the harmful effects of fentanyl and its analogs, which are responsible for a significant number of overdose deaths. The therapy, known as CSX-1004, works by binding to fentanyl in the bloodstream, preventing it from affecting the brain and causing respiratory depression. The approach aims to provide a longer-lasting solution compared to existing treatments like naloxone, which can be less effective against potent fentanyl variants. Patients receiving this treatment would be monitored for its effectiveness and safety through intravenous administration.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with opioid use disorder, particularly those who have experienced issues related to fentanyl use.
Not a fit: Patients who are not struggling with opioid use disorder or those who do not use fentanyl or its analogs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective and longer-lasting treatment option for individuals suffering from opioid use disorder related to fentanyl.
How similar studies have performed: Other research has shown promise with monoclonal antibody therapies for opioid overdose, indicating potential for success with this novel approach.
Where this research is happening
Belmont, United States
- Mclean Hospital — Belmont, United States (Active)
Researchers
- Principal investigator: Desai, Rajeev Indrajit — Mclean Hospital
- Study coordinator: Desai, Rajeev Indrajit
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.